Gilead Sciences
 |
|
| Public | |
| Traded as | |
| Industry |
Pharmaceutics Biotechnology |
| Founded | 1987 |
| Headquarters | Foster City, California, U.S. |
|
Key people
|
John F. Milligan (CEO) John C. Martin (Chairman) |
| Revenue |
 US $30.4 billion (2016)
|
|
US $13.5 billion (2016)
|
|
|
Number of employees
|
7,900 (2015) |
| Website | www |
 |
|
 Gregg Alton of Gilead Sciences & others, "The Evolution of HIV/AIDS Therapies: A Conversation", 2012, Chemical Heritage Foundation
|
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases. The company currently produces a range of commercially available products, most notably the Hepatitis C drugs: Harvoni and Sovaldi.
Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Lanford Wilson featuring the underworld adventures of the patrons of the namesake cafe.
Gilead Sciences was founded in June 1987 by Michael L. Riordan, a medical doctor who was 29 years old at the time. Riordan graduated from Washington University, the Johns Hopkins School of Medicine and the Harvard Business School. Three core scientific advisers worked with Riordan to create the company and establish its scientific vision. These were Peter Dervan of Caltech, Doug Melton of Harvard, and Harold Weintraub of the Fred Hutchinson Cancer Research Center. Riordan served as CEO from inception until 1996.Menlo Ventures, a venture capital firm where Riordan worked for a year, made the first investment in Gilead, of $2 million, and Menlo's partner DuBose Montgomery served as Chairman of the Board until 1993, when Riordan became Chairman. Riordan also recruited as scientific advisers Harold Varmus, a Nobel laureate who later became Director of the National Institutes of Health, and Jack Szostak, recipient of the Nobel Prize for Physiology or Medicine in 2009.
...
Wikipedia